Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial.
Zhang Z, Heerspink HJL, Chertow GM, Correa-Rotter R, Gasparrini A, Jongs N, Langkilde AM, McMurray JJV, Mistry MN, Rossing P, Toto RD, Vart P, Nitsch D, Wheeler DC, Caplin B. Zhang Z, et al. Among authors: jongs n. Lancet Planet Health. 2024 Apr;8(4):e225-e233. doi: 10.1016/S2542-5196(24)00026-3. Lancet Planet Health. 2024. PMID: 38580424 Free article. Clinical Trial.
Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.
Heerspink HJL, Stack AG, Terkeltaub R, Jongs N, Inker LA, Bjursell M, Maklad N, Perl S, Eklund O, Rikte T, Sjöström CD, Perkovic V; SAPPHIRE Investigators. Heerspink HJL, et al. Among authors: jongs n. J Am Soc Nephrol. 2024 May 1;35(5):594-606. doi: 10.1681/ASN.0000000000000326. Epub 2024 Feb 20. J Am Soc Nephrol. 2024. PMID: 38564654 Clinical Trial. No abstract available.
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
Heerspink HJ, Provenzano M, Vart P, Jongs N, Correa-Rotter R, Rossing P, Mark PB, Pecoits-Filho R, McMurray JJ, Langkilde AM, Wheeler DC, Toto RB, Chertow GM. Heerspink HJ, et al. Among authors: jongs n. Am Heart J. 2024 Apr;270:125-135. doi: 10.1016/j.ahj.2024.02.006. Epub 2024 Feb 15. Am Heart J. 2024. PMID: 38367893 Free article. Clinical Trial.
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.
Koshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD, Rossing P, Correa-Rotter R, McMurray JJV, Górriz JL, Isidto R, Kashihara N, Langkilde AM, Wheeler DC, Heerspink HJL. Koshino A, et al. Among authors: jongs n. NEJM Evid. 2023 Jun;2(6):EVIDoa2300049. doi: 10.1056/EVIDoa2300049. Epub 2023 May 19. NEJM Evid. 2023. PMID: 38320128 Clinical Trial.
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Yu MK, Vart P, Jongs N, Correa-Rotter R, Rossing P, McMurray JJV, Hou FF, Douthat W, Khullar D, Langkilde AM, Wheeler DC, Heerspink HJL, Chertow GM. Yu MK, et al. Among authors: jongs n. J Gen Intern Med. 2024 May;39(6):921-930. doi: 10.1007/s11606-023-08397-9. Epub 2023 Dec 14. J Gen Intern Med. 2024. PMID: 38097862 Free PMC article. Clinical Trial.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Koshino A, Neuen BL, Jongs N, Pollock C, Greasley PJ, Andersson EM, Hammarstedt A, Karlsson C, Langkilde AM, Wada T, Heerspink HJL. Koshino A, et al. Among authors: jongs n. Cardiovasc Diabetol. 2023 Nov 28;22(1):330. doi: 10.1186/s12933-023-02027-8. Cardiovasc Diabetol. 2023. PMID: 38017482 Free PMC article. Clinical Trial.
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study.
Lieverse TTGF, Puchades MJ, Mulder UDJ, Provenzano M, Krenning G, Jongs N, Wink SE, Slart RHJA, Andreucci M, D'Marco L, De Nicola L, Gorriz JL, Heerspink HJL. Lieverse TTGF, et al. Among authors: jongs n. Diabetes Obes Metab. 2024 Feb;26(2):576-582. doi: 10.1111/dom.15346. Epub 2023 Nov 5. Diabetes Obes Metab. 2024. PMID: 37926904 Clinical Trial.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL. Fletcher RA, et al. Among authors: jongs n. J Am Soc Nephrol. 2023 Dec 1;34(12):1965-1975. doi: 10.1681/ASN.0000000000000248. Epub 2023 Oct 25. J Am Soc Nephrol. 2023. PMID: 37876229
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
Heerspink HJL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB. Heerspink HJL, et al. Among authors: jongs n. J Am Soc Nephrol. 2023 Dec 1;34(12):2025-2038. doi: 10.1681/ASN.0000000000000243. Epub 2023 Oct 24. J Am Soc Nephrol. 2023. PMID: 37872654
51 results